Search results
Showing 2206 to 2220 of 2548 results for methods
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
Discontinued Reference number: GID-TA10133
Discontinued Reference number: GID-TA11007
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued Reference number: GID-TAG278
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Cochlear implants for children and adults with severe to profound deafness (TA566)
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.